Form 4: CEO Dinesh Patel Exercises Options in Protagonist Therapeutics

Protagonist Therapeutics CEO Dinesh V. Patel exercised 75,000 stock options and sold the resulting shares on May 12, 2026.

Summary

• CEO Dinesh V. Patel exercised 75,000 stock options at an exercise price of $21.58 per share.
• Following the exercise, the CEO sold 75,000 shares of common stock at a weighted average price of $100.12 per share.
• The sale transactions occurred at prices ranging from $98.83 to $103.50.
• The CEO's direct beneficial ownership of common stock stands at 523,478 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine executive compensation management rather than a change in company fundamentals.

Positives

• The transaction demonstrates the CEO's ability to realize value from long-term equity compensation.
• The exercise price of $21.58 compared to the sale price of $100.12 reflects significant appreciation in the company's stock value.

Negatives

• The sale of 75,000 shares reduces the CEO's direct equity stake in the company.

Risks

• Future stock price volatility may impact the value of remaining unexercised options.
• The expiration of remaining options on October 11, 2026, necessitates future decisions regarding exercise or forfeiture.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person committed to providing full information regarding the number of shares sold at each separate price upon request by the SEC, the Issuer, or a security holder.

Industry Context

StockSavvy.ai notes that executive stock sales are common in the biotechnology sector, often occurring as part of pre-planned liquidity events or to manage tax obligations as options approach expiration.

Comparison to Industry Standards

• The exercise and sale of equity by a CEO is a standard practice for long-term incentive compensation management.
• The transaction volume is consistent with typical executive compensation structures in mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders should note the reduction in the CEO's direct holdings, though the remaining stake remains significant.

Next Steps

• Monitor future Form 4 filings for additional option exercises as the October 2026 expiration date approaches.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Dinesh Patel, Stock Options, Biotech